A Preview Of BioCryst Pharma's Earnings
Portfolio Pulse from Benzinga Insights
BioCryst Pharma (NASDAQ:BCRX) is scheduled to release its quarterly earnings report on 2024-02-26, with analysts expecting an EPS of $-0.24. The company's past earnings performance shows a history of beating EPS estimates, which has positively impacted its share price. However, shares have declined 36.66% over the last 52 weeks, indicating a bearish outlook among long-term shareholders. Investors will be keenly watching for not only the earnings results but also the company's guidance for future growth.
February 23, 2024 | 7:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
BioCryst Pharma is expected to report an EPS of $-0.24 for the quarter. Historical data shows positive share price movement following earnings beats. However, a 36.66% decline in share price over the past year indicates a bearish long-term sentiment.
The expected EPS and historical performance suggest potential for a positive short-term reaction if BioCryst Pharma beats estimates again. However, the significant yearly decline in share price reflects underlying long-term concerns that may temper any short-term gains.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100